EUVIMEDEUVIMED entdecken
Crossref

Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance

Aswin A. Anil, Aishwarya Laxmi Krishnan, Prashant Chandra, Mazhuvanchery Kesavan Unnikrishnan

Journal of Applied Pharmaceutical Science · 2025-03 · 15 (3) · 030-038

DOI: 10.7324/japs.2025.204843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Pharmaceutical Science, online erschienen am 01.03.2025. Verfasst von Aswin A. Anil und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Anil, A. A., Krishnan, A. L., Chandra, P., & Unnikrishnan, M. K. (2025). Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance. Journal of Applied Pharmaceutical Science, 15(3), 030-038. https://doi.org/10.7324/japs.2025.204843

Vancouver

Anil AA, Krishnan AL, Chandra P, Unnikrishnan MK. Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance. Journal of Applied Pharmaceutical Science. 2025;15(3):030-038. doi:10.7324/japs.2025.204843

BibTeX
@article{Anil2025,
  author = {Anil, Aswin A. and Krishnan, Aishwarya Laxmi and Chandra, Prashant and Unnikrishnan, Mazhuvanchery Kesavan},
  title = {Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance},
  journal = {Journal of Applied Pharmaceutical Science},
  year = {2025},
  volume = {15},
  number = {3},
  pages = {030--038},
  doi = {10.7324/japs.2025.204843}
}
Kostenlos starten →